Bactiguard Holding
ISIN: SE0005878741 | Ticker: BACTI | LEI: 549300PAEBW7IAMOSO21
Country: Sweden
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly.
2005
HeadquartersAlfred Nobels Allé 150, 14621 Tullinge – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 675,221,000.00 | 849,289,000.00 | 807,703,000.00 |
| Noncurrent Assets | N/A | 563,875,000.00 | 528,947,000.00 | 499,344,000.00 |
| Property Plant And Equipment | N/A | 108,172,000.00 | 100,646,000.00 | 99,629,000.00 |
| Buildings | N/A | 13,509,000.00 | 14,132,000.00 | 15,097,000.00 |
| Machinery | N/A | 7,981,000.00 | 10,465,000.00 | 18,027,000.00 |
| Goodwill | N/A | 245,411,000.00 | 247,485,000.00 | 250,466,000.00 |
| Brand Names | N/A | 26,155,000.00 | 26,015,000.00 | 25,875,000.00 |
| Recipes Formulae Models Designs And Prototypes | N/A | 149,652,000.00 | 124,245,000.00 | 98,838,000.00 |
| Other Noncurrent Receivables | N/A | 1,708,000.00 | 1,674,000.00 | 1,310,000.00 |
| Deferred Tax Assets | N/A | N/A | N/A | 1,785,000.00 |
| Current Assets | N/A | 111,346,000.00 | 320,342,000.00 | 308,359,000.00 |
| Inventories | N/A | 34,161,000.00 | 36,064,000.00 | 44,367,000.00 |
| Current Trade Receivables | N/A | 49,642,000.00 | 43,157,000.00 | 47,126,000.00 |
| Other Current Receivables | N/A | 6,738,000.00 | 7,162,000.00 | 7,285,000.00 |
| Cash and cash equivalents | 22,878,000.00 | 9,886,000.00 | 217,587,000.00 | 197,727,000.00 |
| Equity And Liabilities | N/A | 675,221,000.00 | 849,289,000.00 | 807,703,000.00 |
| Equity | N/A | 373,349,000.00 | 541,450,000.00 | 495,709,000.00 |
| Issued Capital | N/A | 839,000.00 | 876,000.00 | 876,000.00 |
| Retained Earnings | N/A | -327,492,000.00 | -386,265,000.00 | -439,141,000.00 |
| Additional Paidin Capital | N/A | 707,805,000.00 | 930,680,000.00 | 930,680,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 373,349,000.00 | 541,450,000.00 | 495,709,000.00 |
| Liabilities | N/A | 301,873,000.00 | 307,839,000.00 | 311,994,000.00 |
| Noncurrent Liabilities | N/A | 266,259,000.00 | 245,628,000.00 | 227,784,000.00 |
| Deferred Tax Liabilities | N/A | 11,980,000.00 | 7,320,000.00 | 0.00 |
| Longterm Borrowings | N/A | 188,016,000.00 | 180,663,000.00 | 179,265,000.00 |
| Current Liabilities | N/A | 35,614,000.00 | 62,211,000.00 | 84,210,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 8,801,000.00 | 27,904,000.00 | 33,821,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 19,413,000.00 | 33,052,000.00 |
| Other Current Payables | N/A | 3,991,000.00 | 5,242,000.00 | 6,422,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 172,315,000.00 | 169,486,000.00 | 223,560,000.00 |
| Other Income | 13,711,000.00 | 9,562,000.00 | 29,935,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -4,700,000.00 | -3,057,000.00 | -3,890,000.00 |
| Other Work Performed By Entity And Capitalised | 3,959,000.00 | 2,412,000.00 | 540,000.00 |
| Raw Materials And Consumables Used | 43,853,000.00 | 44,152,000.00 | 47,846,000.00 |
| Employee Benefits Expense | 67,188,000.00 | 84,692,000.00 | 105,060,000.00 |
| Depreciation And Amortisation Expense | 44,293,000.00 | 47,004,000.00 | 49,240,000.00 |
| Other Expense By Nature | 7,659,000.00 | 6,756,000.00 | 28,214,000.00 |
| Profit Loss From Operating Activities | -17,638,000.00 | -54,188,000.00 | -55,667,000.00 |
| Finance Income | 2,240,000.00 | 7,008,000.00 | 12,716,000.00 |
| Finance Costs | 26,535,000.00 | 16,072,000.00 | 16,904,000.00 |
| Profit Loss Before Tax | -41,933,000.00 | -63,252,000.00 | -59,855,000.00 |
| Profit (loss) | -38,388,000.00 | -58,773,000.00 | -52,876,000.00 |
| Profit Loss Attributable To Owners Of Parent | -38,388,000.00 | -58,773,000.00 | -52,876,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -38,388,000.00 | -58,773,000.00 | -52,876,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -5,054,000.00 | -3,720,000.00 | -7,936,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | 873,000.00 | -4,105,000.00 | 4,948,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -730,000.00 | 17,993,000.00 | 4,113,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | -10,023,000.00 | 7,418,000.00 | 15,343,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 44,293,000.00 | 47,004,000.00 | 49,240,000.00 |
| Other Adjustments For Noncash Items | N/A | 5,415,000.00 | 1,574,000.00 | 207,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 702,000.00 | 7,256,000.00 | 3,062,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 41,663,000.00 | 0.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 10,447,000.00 | 4,585,000.00 | 9,842,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 4,903,000.00 | 2,710,000.00 | 1,076,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -57,013,000.00 | -7,295,000.00 | -10,918,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 228,000,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 43,441,000.00 | 0.00 | N/A |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 1,376,000.00 | 562,000.00 | 900,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 5,498,000.00 | 8,618,000.00 | 12,809,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | 781,000.00 | -4,137,000.00 | -1,144,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 46,204,000.00 | 205,827,000.00 | -13,892,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -10,107,000.00 | 205,788,000.00 | -21,748,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -2,886,000.00 | 1,913,000.00 | 1,888,000.00 |
| Cash and cash equivalents | 22,878,000.00 | 9,886,000.00 | 217,587,000.00 | 197,727,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 11.08.23 | Mikael Sander | Other | Buy | SEK 46,760.00 |
| 12.05.23 | Mikael Sander | Other | Buy | SEK 356,720.00 |
| 08.05.23 | Mikael Sander | Other | Buy | SEK 343,280.00 |
| 08.05.23 | Thomas von Koch | Other | Other | SEK 123,919.12 |
| 08.05.23 | Mikael Sander | Other | Buy | SEK 123,919.12 |
| 02.05.23 | Thomas von Koch | Other | Buy | SEK 17,092.50 |
| 28.04.23 | Thomas von Koch | Other | Buy | SEK 24,343,955.51 |
| 14.12.22 | Thomas von Koch | Other | Other | SEK 1,000,004.10 |
| 07.11.22 | TomEnterprise Public Capital AB | Other | Buy | SEK 35,686,980.00 |
| 07.11.22 | TomEnterprise Public Capital AB | Other | Buy | SEK 23,625,000.00 |
SE0005878741
LEI549300PAEBW7IAMOSO21
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.